Milestone Pharmaceuticals Inc.
MIST
$1.07
-$0.06-4.89%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 67.55% | 39.00% | 64.27% | 47.03% | 25.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 46.72% | 28.60% | 51.27% | 31.40% | 11.60% |
| Operating Income | -42.46% | -25.18% | -47.59% | -31.40% | -11.60% |
| Income Before Tax | -51.29% | -31.65% | -51.88% | -35.65% | -14.71% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -51.29% | -31.65% | -51.88% | -35.65% | -14.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -51.29% | -31.65% | -51.88% | -35.65% | -14.71% |
| EBIT | -42.46% | -25.18% | -47.59% | -31.40% | -11.60% |
| EBITDA | -42.42% | -25.16% | -47.69% | -31.48% | -11.62% |
| EPS Basic | 17.12% | 12.83% | -17.62% | -1.49% | 17.47% |
| Normalized Basic EPS | 17.17% | 12.86% | -17.63% | -1.51% | 17.45% |
| EPS Diluted | 17.12% | 12.83% | -17.62% | -1.49% | 17.47% |
| Normalized Diluted EPS | 17.17% | 12.86% | -17.63% | -1.51% | 17.45% |
| Average Basic Shares Outstanding | 77.84% | 50.69% | 34.73% | 30.97% | 31.02% |
| Average Diluted Shares Outstanding | 77.84% | 50.69% | 34.73% | 30.97% | 31.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |